Selank matched a benzodiazepine for anxiety in a 62-patient trial

How is Selank supposed to reduce anxiety?

Selank, a synthetic heptapeptide built as a stabilized analog of tuftsin, is proposed to reduce anxiety through GABAergic signaling, enkephalinase inhibition, and BDNF modulation.

Tuftsin is an endogenous peptide fragment of immunoglobulin G with known immunomodulatory roles. Enkephalinase is the enzyme that degrades endogenous enkephalins. Inhibiting it would in theory prolong opioid-peptide activity without the receptor binding profile of an opioid drug.

The BDNF mechanism has direct rat support. In an ethanol-withdrawal model, Selank normalized hippocampal and prefrontal cortex BDNF content alongside improved memory and attention performance ^[4]. That is a specific, peer-reviewed finding about alcohol-withdrawal neuroprotection in rats, not a general claim about human cognitive enhancement.

Does Selank act itself, or through its breakdown products?

Whether Selank's effects come from intact Selank or from its breakdown products is unresolved, because none of the cited human trials measured Selank or its fragments pharmacokinetically.

Selank has a short half-life and is broken down enzymatically. One of its breakdown products, Pro-Gly-Pro, is itself reported to have biological activity in preclinical work.

The question matters for dosing. If a meaningful fraction of any observed effect comes from a metabolite rather than intact Selank, dosing logic built around how much intact peptide reaches the brain rests on a shakier foundation than it appears. Attributing the effect cleanly to Selank is an assumption, not a finding.

Does Selank work as well as a benzodiazepine?

In one 62-patient Russian RCT, intranasal Selank produced anxiolytic effects comparable to the benzodiazepine medazepam, but the trial had no placebo arm ^[1].

The patients had generalized anxiety disorder and neurasthenia. Selank's effects on the Hamilton and Zung scales were comparable to the active comparator's, and the authors reported antiasthenic and psychostimulant effects not seen with medazepam ^[1].

The trial is a real signal worth taking seriously: a randomized, controlled comparison, not an open-label impression. Comparing Selank with an active drug rather than placebo makes it harder to rule out expectation effects or natural symptom fluctuation as contributors. The trial was published only in a Russian-language journal, without independent replication elsewhere.

What other human studies of Selank exist?

Two other human studies add to the Selank record: a 14-day immune-marker study ^[2] and a 30-patient adjustment disorder trial against a waitlist control.

The adjustment disorder trial compared two weeks of Selank with a waitlist control in 30 patients. Somatic symptom scores and alcohol misuse scores were significantly lower in the treatment group, with benefits reported as persisting at four-week follow-up. A waitlist control is a weaker design than placebo, because it cannot separate the drug's specific effect from the general effect of receiving any structured intervention. The persistence of benefit past the treatment window deserves attention rather than dismissal.

The immune study measured immune markers, not mood. Fourteen days of Selank normalized Th1/Th2 cytokine balance and CD4+/CD8+ ratios and enhanced NK cell activity in patients with anxiety-asthenic disorders, with in vitro data showing suppression of IL-6 gene expression ^[2]. The finding is interesting given Selank's lineage, since tuftsin is an immune peptide. It is a study of immune parameters, and it does not validate the anxiolytic claim on its own.

What do rodent studies of Selank show?

In WAG/Rij rats and BALB/c mice, Selank reduced depression-associated behaviors such as immobility and anhedonia, with effects at both high and low dose ranges depending on the model ^[3].

Elevated plus maze and forced swim tests are standard, useful tools for characterizing a compound's behavioral pharmacology in animals. Rodent anxiolysis and human anxiolysis are different questions answered by different kinds of evidence, and the rodent study does not close that gap. Rodent work fills out Selank's mechanistic picture without confirming anything in humans.

How strong is the evidence that Selank treats anxiety?

Selank's anxiety evidence earns a C (moderate) grade: a real signal, plausible mechanism and registration data in one country, but no independently replicated, internationally published, placebo-controlled human trial.

That is a different evidentiary position from "clinically proven anxiolytic," which is how most summaries frame Selank. For the acetylated, amidated variant, see the evidence on N-acetyl Selank amidate. Stack claims are a separate question, covered in the Selank and Semax stack evidence.

Where does the 250 to 750 mcg Selank dose come from?

The 250 to 750 mcg daily Selank range is user convention layered on thin trial data, not a number derived from a dose-response study.

Reported routes include intranasal, sublingual, and subcutaneous injection. Both human trials used the intranasal route, but neither reports the specific mcg dose or full dosing schedule in a way that maps onto the 250 to 750 mcg range circulating in forums and vendor material. For how the route itself works, see how nasal peptides reach the brain.

The two-week duration used in the adjustment disorder trial is one of the only cycle-length numbers with any trial backing. Claims about optimal 2- to 4-week cycling beyond that are extrapolation.

What are the side effects and risks of Selank?

Reported Selank side effects are nasal irritation, burning or congestion with intranasal use, mild fatigue or drowsiness in some users, headache, and altered taste or post-nasal drip.

These are consistent with what is reported for intranasal peptide administration generally. None of the human trials reports serious adverse events, but the samples are small (30 to 62 patients) and the follow-up windows are short (weeks, not months or years). The absence of a signal in those trials is not an established safety profile, and no Western long-term safety database exists.

Selank is registered as a pharmaceutical in Russia and unapproved in the US. The unregulated peptide market has no standardized purity testing, so the purity and sterility of research-use-only product is a bigger practical risk than anything in Selank's pharmacology. See how to read a peptide certificate of analysis.

What is still unknown about Selank?

The cited Selank studies leave four questions open:

• Which molecule acts. No cited study measured Selank or Pro-Gly-Pro levels alongside clinical outcomes, so which molecule drives any reported effect, and whether dose matters the way vendor protocols imply, is unknown.
• Long-term safety. None of the cited studies provides long-term human safety data.
• Dose-response. No dose-response study establishes why one mcg amount would differ meaningfully from another.
• Human BDNF effects. None of the cited trials measured BDNF in humans, so the neuroprotection claim rests on rat data ^[4].